Latest news with #pulsedelectricfield
Yahoo
17-06-2025
- Health
- Yahoo
Endogenex to Present Data on Endoscopic Procedure for Type 2 Diabetes at American Diabetes Association's (ADA) 85th Scientific Sessions
MINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), will present results from its REGENT-1 Australia clinical study at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place in Chicago, June 20 – 23, 2025. The REGENT-1 study assessed the safety and feasibility of the Endogenex Pulsed Electric Field System (the ReCET System) – an investigational, endoscopic outpatient procedure that uses non-thermal energy to treat the inflamed and dysfunctional tissue associated with type 2 diabetic duodenopathy – in the U.S. and Australia. Presentations at ADA will include: Pulsed Electric Field Induced Duodenal Re-Cellularization Impact on Insulin Sensitivity and Beta Cell Function: Results From REGENT-1, An Open-Label, Prospective Study in Type 2 Diabetes Presenter: Elif Ekinci, MBBS, PhD, FRACP Date/Time: June 22, 2025 / 12:30 pm – 1:30 pm CST Location: West Hall, F1 McCormick Center Effects of Energy Dosing on Safety and Efficacy in an Open-Label Study of Endoscopic Pulsed Electric Field Induced Electroporation in Type 2 Diabetes (REGENT-1 Trial) Presenter: David O'Neal, MD Date/Time: June 22, 2025 / 12:30 pm – 1:30 pm CST Location: West Hall, F1 McCormick Center 'As evidence continues to build around the duodenum's role as a metabolic control center, we now recognize that many individuals with type 2 diabetes experience dysfunction rooted in diabetic duodenopathy,' said Dr. Chris Sorli, endocrinologist and Chief Medical Officer at Endogenex. 'Targeting this pathology is a logical and compelling next step. We look forward to sharing new clinical data with the endocrinology community on a novel duodenal recellularization approach that may hold promise in slowing disease progression.' About Endogenex™ Founded in partnership with Mayo Clinic, Endogenex is a medical technology company pioneering a new treatment for type 2 diabetes that targets what research now points to as a likely driver of the disease process: a damaged duodenum. The company's novel, outpatient endoscopic procedure uses non-thermal pulsed electric fields (PEF) energy to treat inflamed and dysfunctional tissue associated with type 2 diabetic duodenopathy. A specialized Endogenex catheter delivers PEF to the mucosa and sub-mucosa duodenal tissue initiating the body's natural process of cell regeneration. Endogenex's goal is to restore the gut to a healthier state, helping patients do more than manage their symptoms — and potentially slow, or even stop, their disease progression. By following the science to the gut, Endogenex aims to redefine what's possible for diabetes care. For more information – including about the ReCET Study, which is currently enrolling new patients – please visit and Media Inquiries: Ashley Biladeau Biladeau Consulting for Endogenexashley@ Krissy WrightChief Financial Officer kwright@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
07-05-2025
- Health
- Reuters
Health Rounds: Procedure that delivers electric pulses to intestine improves type 2 diabetes
May 7 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) High-voltage electrical pulses to the upper region of the small intestine in a minimally invasive procedure can significantly improve type 2 diabetes, researchers reported at the Digestive Disease Week, opens new tab meeting. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. The magnitude of improvement is comparable to the diabetes benefits seen with gastric bypass weight loss surgery, particularly in patients who receive the highest-dose electrical pulses, the researchers said. 'This first-of-its-kind study demonstrates that non-thermal pulsed electric field energy treatment of the duodenum can significantly and durably improve... insulin resistance and beta cell function,' the main body processes involved in type 2 diabetes, Dr. Richard Pratley of the AdventHealth Diabetes Institute in Orlando, Florida, who worked on the study, said in a statement. As nutrients move from the stomach into the small intestine, the cells of the duodenum play a crucial role in glucose regulation. Typically in type 2 diabetes, the duodenum is inflamed and dysfunctional. Delivery of the electric pulses triggers the body to regenerate healthy cells that can help control blood sugar levels. The 51 mostly overweight or obese patients with type 2 diabetes who participated in the trial of the Endogenex Pulsed Electric Field System known as ReCET, showed significant improvements in insulin sensitivity and pancreas beta cell function at 12 weeks, with improvements persisting at 48 weeks, the researchers reported. Patients also had significant improvements in blood sugar control and body weight. The researchers are now testing the procedure in a pivotal trial in overweight individuals with type 2 diabetes inadequately controlled by non-insulin glucose-lowering medications. While the current studies are looking at blood sugar control and weight loss, study leader Dr. Barham Abu Dayyeh of Cedars-Sinai in Los Angeles said the treatment is likely to also work for type 2 diabetes in patients who are not overweight. 'We believe any patient who has type 2 diabetes, is struggling to maintain control of their disease, and is progressing toward (needing multiple diabetes medications) or insulin will be target candidates,' he said. PROCEDURE FOR PREVENTING PANCREATITIS DOESN'T WORK A common surgery done to prevent pancreatitis does not actually work, a new study has found. About one in 10 people are born with a condition called pancreas divisum, in which pancreas ducts fail to fuse properly. While often asymptomatic, it can sometimes be a factor in recurrent pancreatitis, a serious and painful condition. Retrospective studies have suggested that a minimally invasive surgery called endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES) eases acute pancreatitis in 50% to 70% of such patients. However, ERCP itself can cause acute pancreatitis in 10%-20% of patients and may instigate other issues later, such as scarring of the pancreas opening, which may lead to other symptoms, study leader Dr. Gregory Cote of Oregon Health & Science University said in a statement. Despite the known risks of the procedure, until now there have been no trials comparing miES to a sham procedure. At the Digestive Disease Week meeting, his team reported on 148 patients with pancreas divisum and an average of three previous episodes of pancreatitis who were randomly assigned to undergo miES or a sham procedure. During a median follow-up of 33.5 months, there was no statistically significant difference in the number of patients who had another bout of acute pancreatitis. There were also no differences in numbers of patients who reported pancreas-related pain more than a month after the procedure or who developed chronic pancreatitis, diabetes, or inadequate production of digestive enzymes by the pancreas. The findings are 'actually quite extraordinary when you consider that many doctors have advocated for this procedure for decades,' Cote said. 'Guidelines currently recommend/acknowledge pancreas divisum as a risk factor for pancreatitis, and suggest ERCP as a treatment. These guidelines are likely to change based on this study,' he said. He added that some patients with conditions such as a narrowing or blockages of the pancreatic duct might still benefit from ERCP. Patients with those conditions were not included in this study. VASECTOMY RARELY FAILS, BUT SEMEN ANALYSIS SHOULD BE PERFORMED Vasectomy failure is very rare but happens more often than previously believed, researchers reported at the American Urology Association annual meeting, opens new tab in Las Vegas. They said a post-vasectomy semen analysis to ensure that sperm is not present should become routine. Reviewing nearly half a million vasectomies performed between 2007 and 2021, they found a post-vasectomy pregnancy rate of 2.26 for every 1,000 patients observed for one year after the procedure. Historically, the pregnancy rate had been roughly 1 in every 2,000 patients observed for a year. Vasectomy failure rates were highest during the first four months after the procedure, at 4.7 pregnancies per 1,000 per year. Pregnancy rates were lower in patients with older partners and when procedures had been performed more recently. After taking patients' risk factors into account, the researchers saw an increased risk of failure when the doctor performing the vasectomy was not a urologist, when the procedure was done in a doctor's office, or when a semen analysis was not performed after the procedure. (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays)
